- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 797 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 373
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Artery Hypertension
- Interventions
- GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- CT Pulmonary Angiography Scan
- Diagnostic Test
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Gossamer Bio USA, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Shape II CPET
- Device
- Lead sponsor
- Shape Medical Systems, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 6
- States / cities
- Torrance, California • Denver, Colorado • Jacksonville, Florida + 3 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Oral treprostinil (UT-15C) sustained release tablets, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 90 Years
- Enrollment
- 1,899 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2032
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Interventions
- 129Xe Hyperpolarized
- Drug
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pulmonary Hypertension, Mitral Valve Disease
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Durham, North Carolina
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
- Interventions
- Tamoxifen, Placebo Oral Tablet
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
- Biological
- Lead sponsor
- Keros Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more
- Conditions
- PAH
- Interventions
- 75mg CXA-10, 150mg CXA-10, Placebo
- Drug · Other
- Lead sponsor
- Complexa, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Systemic Sclerosis, Pulmonary; Hypertension
- Interventions
- Dimethyl Fumarate (DMF), Placebo Oral Tablet
- Drug
- Lead sponsor
- Robert Lafyatis
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Background PAH Therapy
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan 10 mg, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Placebo, Sotatercept, SOC
- Drug · Other
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more
- Conditions
- Pulmonary Hypertension, Cardiac MRI <40
- Interventions
- Carvedilol
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Inhaled treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Iloprost Inhalation Solution (Ventavis)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- UT-15C SR, treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ventripoint Medical System
- Device
- Lead sponsor
- VentriPoint Diagnostics Ltd.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
- Conditions
- Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Weston, Florida
- Conditions
- Pulmonary Hypertension
- Interventions
- Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more